Janku: Agreements from 93-95%, goes into discrepancies between FFPE and ddPCR #Tricon
3:03pm February 23rd 2017 via Hootsuite
Janku: Showing concordance between KRAS multiplex via ddPCR to FFPE '16 Ann Oncol https://t.co/Spvxhk1Nec #Tricon
3:02pm February 23rd 2017 via Hootsuite
Janku: Plasma positive DNA discrepant compared to BEAMing or ddPCR found 100% concordance, so the prior discrepency was biological #Tricon
2:59pm February 23rd 2017 via Hootsuite
Janku: Shows Idylla data for BRAF V600E, TAT of 1h 15m. Found 88% agreement between cfDNA by Idylla vs FFPE #Tricon
2:58pm February 23rd 2017 via Hootsuite
Janku: Reviewed use for early det, Rx guidance, and surveillance. BEAMing data chart from '15 ref https://t.co/sYIeo2KK9I #Tricon
2:57pm February 23rd 2017 via Hootsuite
Janku: Clinical review of ctDNA '15 https://t.co/faJdFvSAsM #Tricon
2:55pm February 23rd 2017 via Hootsuite
Filip Janku (MD Anderson CC TX) Liquid biopsies in precision oncology #Tricon
2:53pm February 23rd 2017 via Hootsuite
Patel: Needing both strand sequencing; method from Univ WA PNAS '12 https://t.co/jPqUaI1jWM presented at #Tricon
2:48pm February 23rd 2017 via Hootsuite
Patel: Pre-existing modes of damage - De-amination causing C->T; oxidation causes G->T via guanine to 8-oxo-guanine by storage #Trico
2:45pm February 23rd 2017 via Hootsuite
Patel: Early detection - you need broad coverage. Shows chart from '15 ref https://t.co/eUl5Cf0gOo #Tricon
2:44pm February 23rd 2017 via Hootsuite
Patel: Response is not immediate via CT scans; slow enough w/chemo, 'notoriously slow w/immunotherapy' #Tricon
2:41pm February 23rd 2017 via Hootsuite
Patel: Nonresponder shows PIK3CA E542K rising from day 0 trhough day 45, then slow decline. Data overlaid w/RECIST tumor burden data #Tricon
Patel: Immunotherapy is now in vogue; some remarkable, durable responses. Shows data of responder KRAS Q61R declineing 40d on trtmnt #Tricon
2:39pm February 23rd 2017 via Hootsuite
Patel: Showed pre- and post-Rx KRAS mutation in blood, at 50d undetectable going out 5 mos. #Tricon
2:37pm February 23rd 2017 via Hootsuite
Patel: Case study: 75y/o F w/Stg I lung adenocarcinoma; 2.9x2.5cm tumor; KRAS G13R; treated with stereotactic body RT #Tricon
2:36pm February 23rd 2017 via Hootsuite
Patel: Able to get <1b in 100K error rate; 70 amplicons in 35 genes; $20 cost/1mL plasma; can run 100 smpls/HiSeq lane; 1 tube assay #Tri
2:34pm February 23rd 2017 via Hootsuite
Patel: Ref shows spiked-in 0.2% mutant KRAS G12S; used overlapping paired-end sequencing to clean-up errors, along w/barcoding. #Tricon
2:30pm February 23rd 2017 via Hootsuite
Patel: Mainly focuses on PCR-based approaches; uses ultra-deep NGS amplicon approach; 10K to 50K seq depth https://t.co/e4bBCBvHjv #Tricon
2:29pm February 23rd 2017 via Hootsuite
Patel: Their lab mainly focuses on PCR-based approaches; uses ultra-deep NGS amplicon approach; 10K to 50K sequencing depth #Tricon
2:26pm February 23rd 2017 via Hootsuite
Patel: Reviews methods: PCR: mutant enrichment (COLD, LNA/PNA, ARMS) and compartmentalization (dPCR, BEAMing) NGS: Amplicon, hyb #Tricon
2:23pm February 23rd 2017 via Hootsuite
Patel: Cp to ctDNA where at 2w the response marker drops. ctDNA needs to be thought abt differently than protein markers #Tricon#Tricon
2:21pm February 23rd 2017 via Hootsuite
Patel: Shows slide of response markers to chemo cycle #'s, and weeks on Rx: imaging vs protein markers, response lowers slowly #Tricon
2:20pm February 23rd 2017 via Hootsuite
Patel: Protein markers are secreted from live cancer cells; ctDNA is released from dying cancer cells. #Tricon
2:19pm February 23rd 2017 via Hootsuite
Patel: Emphasis today will be on treatment response assesment, and early detection. #Tricon
2:17pm February 23rd 2017 via Hootsuite
Abhijit Patel (Yale CT) Technological challenges and clinical applications of ctDNA #Tricon
2:16pm February 23rd 2017 via Hootsuite
Krishnan: NanoVita instrument, 40min time, shows cfDNA capture and quant in lung, panc cancer pts. Exosomes and cfDNA #Tricon
1:17pm February 23rd 2017 via Hootsuite
Krishnan: Shows linearity of signal to DNA concentration; showing mCRC progression; correlation w/clin status, CEA #Tricon
1:15pm February 23rd 2017 via Hootsuite
Krishnan: To the FDA, cfDNA >300bp. Smear can ID a signal there, showed trace from a prostate cancer pt #Tricon
1:14pm February 23rd 2017 via Hootsuite
Krishnan: Trtmt resp std of care via imaging or limited tumor markers; emerging is liquid biopsies and molecular imaging #Tricon
1:13pm February 23rd 2017 via Hootsuite
Krishnan: Cost of side-effects to immunotherapies add 16-18% to the treatment cost (per Moffitt study) #Tricon
1:11pm February 23rd 2017 via Hootsuite
Krishnan: Treatment response monitoring application: most cancer pts are Stg III-IV, and feel this can help #Tricon
1:09pm February 23rd 2017 via Hootsuite
Krishnan:Shows Biological Dynamics video of how it works https://t.co/K6TNTLSdoO #Tricon
1:08pm February 23rd 2017 via Hootsuite
Krishnan:Currently going through FDA, clin appl for treatment resp monitoring (Class II) #Tricon
1:06pm February 23rd 2017 via Hootsuite
rishnan:Size ranges in blood: <0.01um HSA, Ig, fibrinogen. To 1um: exosomes, large protein aggregates, HMW cfDNA (>300bp), debris #Tri
1:05pm February 23rd 2017 via Hootsuite
Krishnan: 150uL of sample (blood, serum, plasma as native), nanoparticles captures on electrodes; fluidic wash and imaging #Tricon
1:03pm February 23rd 2017 via Hootsuite
Krishnan: Dielectrophoresis (DEP); AC electrothermal flow; AC electro-osmotic flow. Non-uniform electric fields to move particles #Tricon
1:02pm February 23rd 2017 via Hootsuite
Raj Krishnan (Biological Dynamics) Noval AC electrokinetic platform for isolating cfDNA and exosome biomarkers for clinical app's #Tricon
1:01pm February 23rd 2017 via Hootsuite
Bettegowda: Concluded with BRAF detection in CSF, monitoring over 5mos. Ancillary fluids can be a rich source of tumor-spec DNA #Tricon
12:57pm February 23rd 2017 via Hootsuite
Bettegowda: A few lower-grade tumors didn't detect. Recent work on ctDNA in CSF ref https://t.co/JtgQwlHwFH #Tricon
12:54pm February 23rd 2017 via Hootsuite
Bettegowda: Concluded that CNS shed little ctDNA into the blood. For CSF: ctDNA is there. '15 PNAS https://t.co/MX7UzS9pju #Tricon
12:52pm February 23rd 2017 via Hootsuite
Bettegowda: Showed work on pap-smear in '13 Isaac Kinde's work https://t.co/Olp18BwE2H #Tricon
12:51pm February 23rd 2017 via Hootsuite
Bettegowda: Points out Kinde et al '11 PNAS https://t.co/kmU86RoYK4 and description of SafeSeqS. 410 cases https://t.co/hCoiKP1RPe #Tricon
12:43pm February 23rd 2017 via Hootsuite
Bettegowda: Points to this '15 ref https://t.co/H5CSPR4Vzd that describes branched evolution of brain mets, potential targets #Tricon
12:38pm February 23rd 2017 via Hootsuite
Bettegowda: Shows MRI of a glioblasmoma, after Tx what do you say with suboptimal resp. via imaging afterwards? #Tricon
12:36pm February 23rd 2017 via Hootsuite
Bettegowda: As a neurosurgeon, looks at neuro-oncology. PET and CAT scans - shows a lesion, what to say to the pt? #Tricon
12:35pm February 23rd 2017 via Hootsuite
Bettegowda: Shows data of non-synon mutations per tumor from '13 ref https://t.co/gHcnTPu63d #Tricon
12:34pm February 23rd 2017 via Hootsuite
Chetan Bettegowda (Johns Hopkins MD) Tumor derived cell free DNA as a diagnostic tool for human malignancies #Tricon
12:32pm February 23rd 2017 via Hootsuite
Q:Absolute conc helpful? Diehn:Yes, better, they can back into it; they always look at both internally #Tricon
12:26pm February 23rd 2017 via Hootsuite
Q: Early det/localization require imaging? Diehn:Pattern, protein markers, clinical knowledge also helpful about pts #Tricon
12:25pm February 23rd 2017 via Hootsuite
Diehn: Clinical trial results needed for screening. Future effort: further improvements; other markers; other fluids. #Tricon
12:22pm February 23rd 2017 via Hootsuite
